HUMANWELL HEALTHCARE (GROUP) CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.13 CNY | -0.67% |
|
-0.93% | -23.05% |
| Sales 2024 * | 26.63B 3.68B | Sales 2025 * | 28.87B 3.99B | Capitalization | 30.78B 4.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.54B 351M | Net income 2025 * | 2.96B 408M | EV / Sales 2024 * | 1.16 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.07 x |
| P/E ratio 2024 * |
12.3
x | P/E ratio 2025 * |
10.6
x | Employees | 17,676 |
| Yield 2024 * |
2.05% | Yield 2025 * |
2.42% | Free-Float | 61.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.67% | ||
| 1 week | -0.93% | ||
| Current month | -0.88% | ||
| 1 month | -6.41% | ||
| 3 months | -7.32% | ||
| 6 months | -28.49% | ||
| Current year | -23.05% |
1 week
19.03
19.57
1 month
19.0321.04
Current year
17.8525.75
1 year
17.8528.19
3 years
13.1529.13
5 years
9.4739.54
10 years
8.3539.54
| Managers | Title | Age | Since |
|---|---|---|---|
Jie Li
CHM | Chairman | 69 | 03-04-30 |
Xia Fei Deng
PSD | President | 61 | 98-02-28 |
Ya Jun Wu
DFI | Director of Finance/CFO | 54 | 05-03-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Xin Du
CHM | Chairman | 66 | 05-03-27 |
Xiao Dong Zhang
BRD | Director/Board Member | 73 | 05-03-27 |
Xia Fei Deng
PSD | President | 61 | 98-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.67% | 2 M€ | -17.28% | - | |
| 0.57% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 19.13 | -0.67% | 8,474,172 |
| 24-06-05 | 19.26 | -1.13% | 9,509,800 |
| 24-06-04 | 19.48 | +1.56% | 9,102,196 |
| 24-06-03 | 19.18 | -0.62% | 11,022,760 |
| 24-05-31 | 19.3 | -0.05% | 7,971,271 |
End-of-day quote Shanghai S.E., June 05, 2024
More quotes
Humanwell Healthcare (Group) Co., Ltd is a China-based company principally engaged in research and development, manufacture and distribution of medical and pharmaceutical products. The Companyâs products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and others. The Company also provides medical instruments. The Company distributes its products in both domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.13
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.05% | 4.25B | |
| +43.64% | 754B | |
| +39.72% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.64% | 217B | |
| -1.35% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- 600079 Stock
